Boehringer Ingelheim Vetmedica GmbH, Kathrinenhof Research Center, Walchenseestr. 8-12, 83101 Rohrdorf, Germany.
Boehringer Ingelheim Animal Health, 1730 Olympic Drive, Athens, GA 30601, USA.
Parasite. 2021;28:28. doi: 10.1051/parasite/2021024. Epub 2021 Apr 2.
NexGard Combo, a novel topical antiparasitic product for cats, combines the insecticide/acaricide esafoxolaner with the nematocide eprinomectin and cestodicide praziquantel. The efficacy of this combination product was evaluated against two common endoparasites of global occurrence in cats, the nematode Toxocara cati and the cestode Dipylidium caninum, in five controlled studies using naturally or experimentally infected cats with parasites of North American, South African or European origin. Cats evaluated in these studies harbored patent infection of the target parasite confirmed through a pre-treatment fecal examination. In each study, cats were allocated randomly to two groups of equal size (8 or 10 cats per group per study), one group treated with a placebo (mineral oil) and the other with NexGard Combo. Both treatments were administered once as a spot-on at 0.12 mL per kg body weight to deliver the minimum label dosage (1.44 mg/kg esafoxolaner, 0.48 mg/kg eprinomectin, and 10.0 mg/kg praziquantel) to the NexGard Combo-treated cats. To determine efficacy, geometric mean parasite counts seven to 12 days after treatment of placebo-treated (control) cats and NexGard Combo-treated cats were compared. The efficacy of NexGard Combo was 98.8% and 100% against adult T. cati in two studies; and 98.0%, 98.3% and 93.2% against D. caninum in three studies. No adverse events related to treatment were observed throughout the studies. These studies demonstrate high efficacy against these major feline endoparasites and excellent acceptability of the novel topical antiparasitic combination of esafoxolaner, eprinomectin and praziquantel.
NexGard Combo 是一种新型的猫用局部驱虫产品，将杀虫剂/杀螨剂 esafoxolaner 与驱虫药米尔贝肟和驱绦虫药吡喹酮结合在一起。该组合产品的疗效在五项针对猫中两种常见的全球性内寄生虫的对照研究中进行了评估，这两种寄生虫分别是线虫 Toxocara cati 和绦虫 Dipylidium caninum，使用的是来自北美、南非或欧洲的天然或实验感染猫作为研究对象。这些研究中评估的猫都存在目标寄生虫的专利感染，这通过治疗前粪便检查得到了证实。在每项研究中，猫被随机分配到两组，每组大小相等（每组 8 或 10 只猫），一组用安慰剂（矿物油）治疗，另一组用 NexGard Combo 治疗。两种治疗方法均以 0.12 毫升/公斤体重的点涂方式进行一次给药，以达到 NexGard Combo 治疗猫的最低标签剂量（1.44 毫克/公斤 esafoxolaner、0.48 毫克/公斤米尔贝肟和 10.0 毫克/公斤吡喹酮）。为了确定疗效，在治疗安慰剂（对照）猫和 NexGard Combo 治疗猫后 7 至 12 天，比较了几何平均寄生虫计数。在两项研究中，NexGard Combo 对成年 T. cati 的疗效为 98.8%和 100%；在三项研究中，对 D. caninum 的疗效为 98.0%、98.3%和 93.2%。在整个研究过程中，没有观察到与治疗相关的不良反应。这些研究表明，该新型局部驱虫组合对这些主要的猫内寄生虫具有高效性和极好的可接受性。
